RxDoctor Payments Data

Abraham Derman, DO

Internal Medicine · Monroe, NYNPI 1891299038

Payments from drug & device makers

$1,074in general payments, 2019–2025

Across 30 payments — averaging $35.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$266
  • Novo Nordisk$255
  • AstraZeneca$174
  • AbbVie$125
  • Lilly USA, LLC$86
  • Pfizer$61
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$1,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,074 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,337
Medicare patients
30
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide171$180,813
MounjaroTirzepatide132$149,018
FarxigaDapagliflozin Propanediol184$139,354
JardianceEmpagliflozin185$135,397
EliquisApixaban75$68,493
RybelsusSemaglutide38$44,257
DapagliflozinDapagliflozin Propanediol66$40,973
EntrestoSacubitril/Valsartan20$24,148
MyrbetriqMirabegron17$10,137
SynthroidLevothyroxine Sodium22$2,674
Ketoconazole75$2,425
Rosuvastatin Calcium304$2,356
Metoprolol Succinate89$1,159
Atorvastatin Calcium177$1,145
Olmesartan Medoxomil111$1,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$255$225,070209 claims
Lilly USA, LLCMounjaro$86$149,018132 claims
AstraZenecaFarxiga$174$139,354184 claims
PfizerEliquis$61$68,49375 claims
AbbVieSynthroid$125$2,67422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Monroe

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →